Gilead Sciences (GILD) Operating Expenses (2009 - 2026)

Gilead Sciences (GILD) has reported Operating Expenses for 18 consecutive years, with $4.4 billion the latest figure, recorded in Q1 2026.

• Operating Expenses for Q1 2026 came in at $4.4 billion, down 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.4 billion (down 5.6% YoY), and the FY2025 annual result was $19.4 billion, down 28.31% from the prior year.
• Operating Expenses was $4.4 billion for Q1 2026 at Gilead Sciences, down from $5.9 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $11.0 billion in Q1 2024 and troughed at $4.2 billion in Q3 2022.
• Average Operating Expenses over 5 years is $5.3 billion, with a median of $4.6 billion recorded in 2023.
• Year-over-year, Operating Expenses surged 136.88% in 2024 and sank 59.76% in 2025.
• Over 5 years, Operating Expenses stood at $5.1 billion in 2022, then rose by 7.42% to $5.5 billion in 2023, then decreased by 7.0% to $5.1 billion in 2024, then advanced by 16.1% to $5.9 billion in 2025, then fell by 26.38% to $4.4 billion in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $4.4 billion in Q1 2026, $5.9 billion in Q4 2025, and $4.4 billion in Q3 2025.